Vericel to Report Second-Quarter 2019 Financial Results on August 6, 2019
23 Julho 2019 - 9:00AM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell
therapies for the sports medicine and severe burn care markets,
today announced the following webcast and conference call to
discuss its second-quarter 2019 financial results and business
highlights.
What: |
Vericel Corporation Second-Quarter 2019 Earnings Call |
|
|
When: |
Tuesday, August 6, 2019 at 8:00am
(EDT) |
|
|
Where: |
http://investors.vcel.com/events-presentations |
|
|
How: |
The conference call will be
available live in the Investors section of the Vericel website at
http://investors.vcel.com/events-presentations. Please access
the site at least 15 minutes prior to the scheduled start time in
order to download the required audio software if necessary. |
To participate in the live call by telephone, please call (877)
312-5881 and reference Vericel Corporation second-quarter 2019
earnings call. If calling from outside the U.S., please use
the international phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast
will be available at http://investors.vcel.com/events-presentations
until August 6, 2020. A replay of the call will also be
available until 11:00am (EDT) on August 11, 2019 by calling (855)
859-2056, or from outside the U.S. (404) 537-3406. The
conference ID is 6576007.
About Vericel CorporationVericel is a leader in
advanced cell therapies for the sports medicine and severe burn
care markets. The company markets two cell therapy products
in the United States. MACI® (autologous cultured chondrocytes
on porcine collagen membrane) is an autologous cellularized
scaffold product indicated for the repair of symptomatic, single or
multiple full-thickness cartilage defects of the knee with or
without bone involvement in adults. Epicel® (cultured
epidermal autografts) is a permanent skin replacement for the
treatment of patients with deep dermal or full thickness burns
greater than or equal to 30% of total body surface area. The
company also holds an exclusive license for North American
commercial rights to NexoBrid®, a registration-stage biological
orphan product for debridement of severe thermal burns. For
more information, please visit the company's website at
www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. NexoBrid® is a registered trademark of MediWound
Ltd. and is used under license to Vericel Corporation. © 2019
Vericel Corporation. All rights reserved.
Global Media Contacts:David SchullRusso
Partners LLCDavid.schull@russopartnersllc.com+1 212-845-4271
(office)+1 858-717-2310 (mobile)
Karen ChaseRusso Partners LLCKaren.chase@russopartnersllc.com+1
646-942-5627 (office)+1 917-547-0434 (mobile)
Investor Contacts: Chad RubinSolebury
Troutcrubin@troutgroup.com+1 646-378-2947
Lee SternSolebury Troutlstern@troutgroup.com+1
646-378-2922
Vericel (NASDAQ:VCEL)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Vericel (NASDAQ:VCEL)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024